

Ryzodeg® Penfill® & NovoPen® 6 Program

Novo Nordisk is aware that the supply constraints on Ryzodeg® FlexTouch® have impacted both healthcare practitioners and patients and we empathise and hope to work alongside CDEs to ensure a relatively smooth transition of patients to Ryzodeg® Penfill® via a NovoPen® device.

What is the situation?

Novo Nordisk is recommending patients on Ryzodeg® insulin pen (FlexTouch®) are switched to the insulin cartridge (Ryzodeg® Penfill®) which is administered via a new device, NovoPen® 6 – provided to patients at no cost.

Why are we in this situation?

The reason for this is Novo Nordisk is experiencing supply constraints on its FlexTouch® pens. These constraints are a result of unprecedented global demand for other medicines using the FlexTouch® delivery device.

We expect the Ryzodeg® FlexTouch® supply constraint to remain for some time.

What is the solution?

Novo Nordisk has substantial stock levels of an alternate delivery device known as NovoPen® 6. NovoPen® 6 is a new, smart insulin pen that automatically records insulin dosing information at each administration.

The active medicine (Ryzodeg®) does not change with conversion from the FlexTouch® to NovoPen® 6 and it does not affect the efficacy and safety profile of treatment for patients.

Patients can access their NovoPen® 6 at no cost through the NovoPen® 6 Pharmacy Program. Any NovoPen® device is compatible with Penfill® insulin cartridges, and patients may also use NovoPen® 4 or echo to administer their insulin, until they access a NovoPen® 6.

CDEs play a pivotal role in diabetes management and education by providing specialized knowledge, personalized education, and support to improve patient outcomes.

What is the NovoPen® 6 Pharmacy Program?

Patients will be able to access NovoPen® 6 from pharmacies participating in the NovoPen® 6 Pharmacy Program, which is hosted by PharmaPrograms [NovoPen® 6 Pharmacy Program \(pharmaprograms.com.au\)](http://pharmaprograms.com.au).

The program is designed to ensure that patients who have been prescribed a Novo Nordisk insulin cartridge (Penfill®) have access to the NovoPen® 6 device. This distribution model ensures equitable access across Australia.

How will patients access NovoPen® 6 through the centralised Pharmacy Program?

1- Registration Process – patients will need to **register** for the NovoPen® 6 Pharmacy Program.

Patients can register in two ways, either through participating community Pharmacies or through their CDE/HCP/Nurse.

- For *registration* through participating community Pharmacies: Pharmacies participating in the program (NovoPen® 6 Network Pharmacies) can be found via the Online Pharmacy Locator, which is made available for HCPs and patients to access [Pharmacy Locator | NovoPen® 6 \(pharmaprograms.com.au\)](http://pharmaprograms.com.au)
- For *registration* through CDEs: Pharma Programs is updating the website to add the HCP/Nurse/CDE login and registration of patient. However, NovoPen® 6 devices will still need to be collected via nominated retail pharmacies selected by the patient (will be available from July 10th)

2- NovoPen® 6 Collection

Supplies of NovoPen® 6 will only be available through participating community Pharmacies, which are registered in the NovoPen® 6 Pharmacy Program.

- Any community pharmacy in Australia can register to be part of the NovoPen® 6 Pharmacy program by contacting PharmaPrograms.
- PharmaPrograms is available to answer any questions you have via:
 - Phone: 1300 377 781 (9am – 5pm AEST, Monday – Friday) or
 - Email : novopen@pharmaprograms.com.au
- Currently ~80% of community pharmacies in Australia are registered to the NovoPen® 6 Pharmacy program and this continues to expand
- If the patient's preferred pharmacy is not registered to NovoPen® 6 Pharmacy program, the CDE can call PharmaPrograms to ask for the pharmacy to be registered to the Program.

Resources and Patient Support Materials:

To support your practice/clinics, Novo Nordisk will provide the following:

- Every CDE across Australia will receive a NovoPen® 6 demonstration device and resources to provide education to patients requiring a durable device (either NovoPen® 6, NovoPen® 4 or NovoPen Echo®) via their Novo Nordisk Representative.

Materials:

- NovoPen® 6 device (demo only – not to be given to a patient)
- Penfill® Test medium + needles
- Device User Guide + Video QR code
- QR Code for Online Pharmacy Locator (by postcode)

Demo Device for CDEs Nationally:

All CDEs can have a NovoPen® 6 demo device and relevant materials for demonstration purposes.

Please contact your Novo Nordisk Rep if you have not received your demo device.

CDE Device Training:

- Please contact your Novo Nordisk Rep to organise an in-service on how use the NovoPen® 6 device.
- A NovoPen® 6 Device Upskill Deck is also available as a reference/resource.

Novo Nordisk Rep contact details:

- **NSW/ACT Region:**
 - Lily Tomasevic: 0419 619 411 or litm@novonordisk.com
 - Shalini Maharaj: 0417 610 942 or snvm@novonordisk.com
 - Laura Tavares: 0439 272 399 or lrtv@novonordisk.com
 - Kayla Le: 0419 434 654 or xkl@novonordisk.com
 - Michelle Amiri: 0458 746 332 or ymha@novonordisk.com
- **QLD Region:**
 - Al Downes: 0417 028 045 or adwn@novonordisk.com
 - Celeste Jacobs: 0447 071 681 or ceja@novonordisk.com
 - Andrew Barton: 0418 153 154 or aewb@novonordisk.com

- **VIC/TAS Region:**
 - Teresa Kho: 0418 203 421 or trsk@novonordisk.com
 - Hamish Maltby: 0418 527 811 or hmal@novonordisk.com
 - Pan Sood: 0418 101 496 or pkso@novonordisk.com
 - James Tria: 0417 124 298 or ujmt@novonordisk.com
 - Betul Altun: 0409 353 224 or btal@novonordisk.com
- **SA/NT Region:**
 - Aneta Zysk: 0497 385 924 or atzk@novonordisk.com
 - Michael Rosser: 0409 792 385 or umcr@novonordisk.com
- **WA Region:**
 - James Gimblett: 0418 958 662 or jmgb@novonordisk.com
 - Janine Stanley: 0408 150 727 or insn@novonordisk.com

Novo Nordisk Customer Care contact details:

Tel: 1800 668 626

Email: aunrccc@novonordisk.com


Role of Pharmacist in the Program:

- **Register** the patient to the program to access the NovoPen® 6 at no cost to the patient
- **Provide** patient with NovoPen® 6 user guide resource (User guide and video QR code). **Offer** device assistance to the patient (*level of training will vary based on the needs of the patient*).
- **Ensure** all their Ryzodeg® FlexTouch® patients have been transitioned from FlexTouch® to NovoPen® 6.
- Ensure **equitable** access to NovoPen® 6 (all patients will receive one device unless another is needed due to specified reasons).
- Pharmacist to **encourage** patient to visit CDE for additional education & support.

Role of CDEs in the Program: Website Login currently being developed and will go live on July 10th

- **Register** the patient to the program to access the NovoPen® 6 at no cost from the registered pharmacy that was chosen via the Online Pharmacy Locator.
- **Direct** the patient to collect the NovoPen® 6 device from pharmacy.
- **Educate** the patient on how to use the device.

CDE Facilitated Patient Enrolment



NovoPen® 6 accessible at no cost to patients:

Patients provided an insulin cartridge (Ryzodeg® Penfill®) will be provided a NovoPen® 6 – at no cost.

Ryzodeg® Scripts:

Novo Nordisk is expecting the availability of Serious Scarcity Script Instrument (SSSI) for pharmacists, enabling Pharmacists to automatically substitute Ryzodeg® FlexTouch® for Penfill® starting from 7th July. This implementation aims to alleviate the inconvenience for patients, eliminating the need for patients to revisit their doctor to obtain a new script.



This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

**PBS Information: Ryzodeg® 70/30 is listed on the PBS
for treatment of diabetes mellitus.**

Please review full Product Information before prescribing, available [here](#).

References: 1. NovoPen® 6 User Guide. 2. Ryzodeg® 70/30 Product Information. 3. Sangave NA et al. Diabetes Spectr. 2019;32(4):378-384.

Novo Nordisk Pharmaceuticals Pty Ltd, ABN 40 002 879 996, Level 10, 118 Mount Street, North Sydney NSW 2060. Novo Nordisk Customer Care (Australia) 1800 668 626. www.novonordisk.com.au. ® Registered trademark of Novo Nordisk A/S. AU23RZG00043. July 2023.

RYZODEG® 70/30
70% insulin degludec and 30% insulin aspart

